“Patients are at the heart of what we do”

David Veitch

CEO

UBS Global Healthcare Virtual Conference
May 26, 2021

At a glance

- Well funded, commercial-stage biopharmaceutical company with significantly growing cash flows from commercialized products
- Focused in the areas of oncology and infectious diseases
- Potential for sustainable growth and value creation based on commercialized brands and an innovative pipeline
- Experienced people with the proven expertise to take compounds from research to market
- Two revenue generating hospital anti-infective brands, Cresemba® and Zevtera® and two clinical oncology drug candidates
- Recognized ability to establish and manage partnerships in both the development and commercial phase, providing access to international markets
- Listed on SIX Swiss Stock Exchange, SIX: BSLN
- Based in life sciences hub, Basel, Switzerland

Potential for sustainable growth and value creation based on commercialized brands and innovative pipeline



Global coverage — Cresemba®



The company we keep — established strong partnerships

License partners

Pfizer Europe (excl. Nordics), China Asia-Pacific, Russia, Turkey and Israel (Cresemba®)	astellas U.S. (Cresemba®)
AsahiKASEI Japan (Cresemba®)	CR Gosun China (Zevtera®)

Distribution partners

ADVANZ PHARMA Europe (excl. Nordics), Israel (Zevtera®)	hikma. MENA region (Cresemba® and Zevtera®)	Knight GBT Grupo Biotoscana LatAm (Cresemba® and Zevtera®)
UNIMEDIC® PHARMA Nordics (Cresemba® and Zevtera®)	AVIR PHARMA Canada (Cresemba® and Zevtera®)	



Antifungal

Cresemba® (isavuconazole)

Invasive mold infections

The market — Invasive fungal infections

- Severe, potentially life-threatening infections mainly affecting immunocompromised patients
- An important cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens
- Rising number of immunocompromised patients
  (cancer and transplantations) driving therapeutic demand
- Mucorales infections on the rise – doubled from 2000 to 2013
- Limitations of current therapies (spectrum of activity, toxicity, effective plasma levels) drive the need for new agents



**Kullberg/Arendrup *N Engl J Med* 2015, Baddley *Clin Infect Dis* 2010, Roden *Clin Infect Dis* 2005, Greenberg *Curr Opin Infect Dis* 2004

Cresemba continues strong in-market sales uptake

USD 256 mn "in-market" sales in the 12 months to December 2020



LCD: USD corrected for currency fluctuations; MAT: Moving annual total; Source: IQVIA, December 2020

Sales of best-in-class antifungals* by product

USD 3.0 bn sales (MAT Q4 2020)

- Potential to increase Cresemba® (isavuconazole) market share
  - Anticipate to be launched in 60 countries by end-2021
  - Exclusivity through 2027 in the U.S. and potential pediatric exclusivity extension to 2027 (from 2025) in the EU



* Best-in-class antifungals: isavuconazole, posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations;
Source: IQVIA, December 2020

Antibacterial

Zevtera® (ceftobiprole)

Severe bacterial infections

Zevtera® — An introduction

- Broad-spectrum anti-MRSA cephalosporin (including Gram-negative bacteria)
- Rapid bactericidal activity
- Potential to replace antibiotic combinations
- Early improvement in HAP, particularly in patients with MRSA, and CAP, including high-risk patients
- Cephalosporin class safety profile
- Marketed in selected countries in Europe, Latin America and the MENA-region as well as in Canada



Approved in major European countries & several non-European countries for both hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and community-acquired pneumonia (CAP). Not approved in the U.S.

MENA: Middle East and North Africa

The hospital anti-MRSA antibiotic market — A USD 2.6 bn market* with the U.S. being the most important region

Daptomycin sales by region (2015, before LOE)



Ceftaroline sales by region (MAT Q4 2020)



* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, oritavancin, and tedizolid

MRSA: Methicillin-resistant *Staphylococcus aureus*; LOE: Loss of exclusivity; ROW: Rest of world
MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations; Source: IQVIA, December 2020

Strategy for accessing the U.S. market

- Two cross-supportive phase 3 studies under FDA Special Protocol Assessment (SPA)

1. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)[1] successfully completed

TARGET
ABSSSI Study

2. *Staphylococcus aureus* bacteremia (SAB)[2] ongoing, topline results from phase 3 study expected in H1 2022

ERADICATE
SAB Study

- Phase 3 program largely funded by BARDA (up to USD ~130 mn, ~70% of total program costs)

BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY
BARDA

- Qualified Infectious Disease Product (QIDP) designation extends U.S. market exclusivity to 10 years from approval

[1] Overcash JS et al. ECCMID 2020, abstract 1594. (NCT03137173)
[2] Hamed K et al. Future Microbiol. 2020;15:35-48. (NCT03138733)

Oncology

Derazantinib

FGFR-driven tumors

Targeting FGFR-driven tumors as single agent and in combination with immunotherapy

- Small molecule, oral inhibitor of FGFR family of kinases
- Development strategy focused on achieving differentiation by leveraging unique properties of derazantinib
  - Kinase inhibition profile: exploring therapeutic potential of additional targets of derazantinib such as CSF1R and VEGFR2 kinase
  - Safety profile: exploring relevance for potential combination therapies
- Three clinical studies ongoing
  - FIDES-01 (Ph 2) in intrahepatic cholangiocarcinoma (iCCA)
  - FIDES-02 (Ph 1/2) in urothelial cancer
  - FIDES-03 (Ph 1/2) in gastric cancer



Sources: Helsten et al., Clin Cancer Res 2016 (22), 257-267; FGFR2 fusions in iCCA: Graham et al. Hum Pathol 2014 (45), 1630-1638; Jain et al. JCO Precis Oncol 2018 (2) 1-12

Phase 2 study in iCCA* – established clinical proof of concept in FIDES-01

FIDES-01 Cohort 1
(N=103)

FGFR2 fusions
(~15% of iCCA)

Topline results:
ORR: 20.4%
Median PFS: 6.6 months

- Consistent with earlier Phase1/2 data[1] and with interim analysis from FIDES-01
- Clinical proof of concept for derazantinib as monotherapy in its first indication established

FIDES-01 Cohort 2
(N=43) - ongoing

FGFR2 mutations/amplifications
(~5% of iCCA)

Pooled data from 23 patients
(clinical studies/EAP)[2]
Median PFS 7.2 months

Interim results (n=14):
DCR: 79% (1 confirmed CR, 1 unconfirmed PR, 9 SD)

- Encouraging PFS in pooled analysis consistent with outcome in patients with FGFR2 gene fusions
- Interim analysis successfully completed based on at least 8 patients with PFS >3 months (PFS not yet mature)
- Topline results expected H1 2022

Manageable safety profile with low incidence of nail toxicity, retinal events, hand-foot syndrome and stomatitis

FIDES-01: NCT03230318
[1]Mazzaferro et al. Br J Cancer. 2019
[2]Droz Dit Busset et al. Annals of Oncology (2020) 31 (suppl_5): abstract 45P (NCT01752920, NCT03230318)

*in patients who progressed after at least one prior systemic chemotherapy regimen

Clinical program in urothelial cancer – FIDES-02

Multi-cohort phase 1b/2 study of derazantinib monotherapy or in combination with atezolizumab in patients with urothelial cancer harboring FGFR genetic aberrations

- Substudies (N≈300) in various treatment settings, including:
  - Post-chemotherapy/immunotherapy recurrence (second-line and post second-line)
  - First-line platinum-ineligible, PD-L1-low
  - Resistance to prior FGFR-inhibitor treatment
- Successful completion of phase 1b cohort
  - Recommended phase 2 dose for the combination established
  - No dose-limiting toxicities observed
- Clinical supply agreement with Roche for atezolizumab
- Plan to amend the study protocol to explore a higher dose of derazantinib in two cohorts of this study
  - Supported by the observed safety and tolerability profile of derazantinib at the current dose of 300 mg per day
  - May provide additional benefits in monotherapy and combination to patients with FGFR-positive urothelial cancer
  - Considers the evolving treatment and competitive landscape in urothelial cancer in patients both with and without FGFR genetic aberrations
- Interim results in derazantinib monotherapy expected H1 2021
- Interim results in combination therapy with atezolizumab expected H2 2021

FIDES-02: NCT04045613; Chaudhry A et al. Journal of Clinical Oncology 2020; 38, no. 6_suppl. TPS590

Clinical program in gastric cancer – FIDES-03

Multi-cohort Phase 1b/2 study of derazantinib as monotherapy or in combination therapy with standard of care (ramucirumab/paclitaxel) or atezolizumab in patients with advanced HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations

- Substudies using derazantinib monotherapy or combination treatment, including:
  - Derazantinib monotherapy in various molecular subtypes
  - Combination of derazantinib with ramucirumab/paclitaxel
  - Combination of derazantinib with atezolizumab
- Clinical supply agreement with Roche for atezolizumab
- Clinical trial collaboration and supply agreement with Lilly for ramucirumab
- Interim results in derazantinib monotherapy and recommended phase 2 dose of derazantinib in combination with ramucirumab/paclitaxel expected H2 2021

FIDES-03: NCT04604132

FGFR-inhibitors show differences in safety profiles

	Cholangiocarcinoma				Urothelial cancer	
	DZB[1] (N=44)	**INF[2] (N=71)**	**FUT[3] (N=67)**	**PEM[4] (N=146)**	**PEM[5] (N=108)**	**ERD[6] (N=87)**
Dosing regimen	300mg QD	125mg Q4W QD for 3w	20 mg QD	13.5mg Q3W QD for 2w	13.5mg Q3W QD for 2w	8 mg QD (titration to 9mg)
Most frequent safety events	Phosphorus⇧ Nausea Vomiting	Phosphorus⇧ Fatigue Stomatitis	Phosphorus*⇧ Diarrhea* Dry mouth*	Phosphorus⇧ Alopecia Diarrhoea	Diarrhoea Alopecia Constipation	Phosphorus⇧ Stomatitis Fatigue
Blood phosphorus⇧†	**59%**	**73%**	**88%**	**60%**	**31%**	**76%**
Fatigue†	**43%**	**49%**	*NR*	**42%**	**32%**	**54%#**
Alopecia†	**20%**	**38%**	*NR*	**49%**	**40%**	**26%**
Dry eye/xerophthalmia†	**16%**	**32%**	*NR*	**35%#**	*NR*	**28%#**
Retinopathy¶	**0%**	*NR*	**9%**	**6%‡**	*NR*	**25%**
Alanine aminotransferase (ALT) ⇧	**30%****	*NR*	*NR*	**43%****	*NR*	**41%****
Hand-foot syndrome/PPE	**0%**	**27%**	**18%**	**15%**	*NR*	**26%**
Nail toxicities	**<5%**	*NR*	**42%**	**43%#**	*NR*	**41%#**
Stomatitis	**11%**	**45%**	*NR*	**35%**	**34%**	**56%**

[1] Droz Dit Busset et al., ESMO 2019 and Basilea data on file, [2] Javle et al., ESMO 2018, [3] Goyal et al., ASCO 2020, [4] Pemazyre™ U.S. Prescribing Information (April 2020), [5] Necchi, et al., ESMO 2018, [6] Balversa™ U.S. prescribing information (April 2019)

† assumed FGFR inhibitor class-effect; *futibatinib treatment-related adverse events

includes various and different adverse reactions; for details see Pemazyre™ U.S. Prescribing Information (April 2020) and Balversa™ U.S. prescribing information (April 2019);

¶ Refers to reported adverse events of Retinal Pigment Epithelial Detachment (RPED) for pemigatinib, Central Serous Retinopathy (CSR)/RPED for erdafitinib and CSR for futibatinib

‡ reported incidence is from 466 patients who received Pemazyre™ across clinical trials;

** based on reported adverse events for DZB; based on reported laboratory abnormalities, regardless of causality for PEM and ERD.

Abbreviations: DZB: derazantinib, INF: infigratinib (BGJ398), FUT: futibatinib (TAS-120), PEM: pemigatinib (INCB54828), ERD: erdafitinib; PPES: Palmar-plantar erythrodysesthesia; NR: not reported; QD: daily; Q3W/Q4W: every 3/4 weeks; w: weeks

Oncology

Lisavanbulin (BAL101553)

Glioblastoma
and other solid tumors

Novel tumor checkpoint controller crossing the blood-brain barrier

- Novel compound inducing tumor cell death through spindle assembly checkpoint activation
- Targeting diverse tumor types resistant to standard therapeutic approaches
- Flexible dosing potential, including daily oral dosing
- Comprehensive biomarker program to optimize patient selection
- Crosses the blood-brain barrier with potent activity in brain tumor models alone and in combination



* Lisavanbulin (BAL101553) is a prodrug of BAL27862

Biomarker-driven phase 2 study ongoing in recurrent glioblastoma

- EB1 (end-binding protein 1) is located on the microtubules and involved in microtubule dynamics and has been shown to be a response predictive marker for lisavanbulin in preclinical studies
- Strong EB1 staining was observed in a patient with an exceptional response to daily oral lisavanbulin in the phase 1 dose-escalation study in recurrent glioblastoma[1]
  - Patient ongoing for more than two years
  - >80% reduction in glioblastoma tumor size
- Interim results expected H2 2021

[1] Lopez et al. Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller, in adult patients with progressive or recurrent glioblastoma or high-grade glioma. JCO 2019;37:15 suppl, 2025 (NCT02490800)

Glioblastoma tumor size reduction in an exceptional responder and EB1 staining of glioblastoma tissue compared to non-responding patients



Baseline (May 2018)



Post Cycle 12 (April 2019)



Responder



Non-responder

Financials & Outlook

Financial guidance

In CHF mn	FY 2020	FY 2021 guidance
Total revenue	127.6	128 - 138
thereof: Contributions Cresemba® & Zevtera® non-deferred deferred	 78.2 33.8	 108 - 118 2.5
Operating loss	8.2	13 - 23
Cash and investments*	167.3	155 – 160**

Continued strong double-digit growth in Cresemba & Zevtera non-deferred revenue contributions Y-o-Y, CHF mn



*Cash, cash equivalents, restricted cash and investments / **Excluding any potential impact from a reduction of the outstanding convertible bonds

Milestones & Outlook 2021 / 2022

Cresemba® & Zevtera® — Increasing cash flows
By the end of 2021, Cresemba to be on the market in 60 countries

		H1 2021	H2 2021	H1 2022	H2 2022
Isavuconazole		✓ Complete patient enrolment in phase 3 study in Japan	Topline results from phase 3 study in Japan		
Ceftobiprole			Complete patient enrolment in SAB phase 3 study	Topline results from SAB phase 3 study	
Derazantinib	**FIDES-01 (iCCA)**	✓ Topline results (FGFR2 fusions)			
		✓ Interim results (other FGFR2 gene aberrations)		Topline results (other FGFR2 gene aberrations)	
	FIDES-02 (urothelial cancer)	Interim results in derazantinib monotherapy	Interim results in combination therapy with atezolizumab		Topline results in combination therapy with atezolizumab
	FIDES-03 (gastric cancer)		Interim results in monotherapy and recommended phase 2 dose with ramucirumab/paclitaxel		Interim results in combination with ramucirumab/paclitaxel
Lisavanbulin			Interim results from phase 2 biomarker-driven glioblastoma study	Topline results from phase 2 biomarker-driven glioblastoma study	
			Recommended phase 2 dose in phase 1 study in newly-diagnosed glioblastoma in combination with radiotherapy		

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law. Derazantinib and its uses are investigational and have not been approved by a regulatory authority for any use. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in nonclinical/preclinical studies to humans is currently being evaluated.

Focused on Growth and Innovation

Grenzacherstrasse 487
PO Box
4005 Basel
Switzerland

investor_relations@basilea.com
www.basilea.com